Browsing by Subject Carcinoma, Non-Small-Cell Lung

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 18 of 18
Issue DateTitleAuthor(s)
2017Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial.
2018An epigenomic approach to identifying differential overlapping and cis-acting lncRNAs in cisplatin-resistant cancer cells.
2017-10-01Antitumor activity of lurbinectedin (PM01183) and doxorubicin in relapsed small-cell lung cancer: results from a phase I study.
2015-12-07BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer.
2015Biomarkers of erlotinib response in non-small cell lung cancer tumors that do not harbor the more common epidermal growth factor receptor mutations.
2018Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain.
2018-10Comparison of plasma ctDNA and tissue/cytology-based techniques for the detection of EGFR mutation status in advanced NSCLC: Spanish data subset from ASSESS.
2017First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.
2018Health care resource use among patients with advanced non-small cell lung cancer: the PIvOTAL retrospective observational study.
2018Molecular testing and treatment patterns for patients with advanced non-small cell lung cancer: PIvOTAL observational study.
2017-12-10Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057).
2016-01-26Optimal sequence of tests for the mediastinal staging of non-small cell lung cancer.Luque, Manuel; Díez, Francisco Javier; Disdier, Carlos
2017Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection.
2017-08-20Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH).
2017-11Systemic therapy treatment patterns in patients with advanced non-small cell lung cancer (NSCLC): PIvOTAL study.
2015-08-07Telomere length and telomerase activity in non-small cell lung cancer prognosis: clinical usefulness of a specific telomere status.
2018The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib.
2017Veliparib in combination with whole-brain radiation therapy for patients with brain metastases from non-small cell lung cancer: results of a randomized, global, placebo-controlled study.